New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
16:02 EDTCLVSClovis receives breakthrough therapy designation for CO-1686
Clovis Oncology announced that the FDA has granted Breakthrough Therapy designation for the company’s investigational agent CO-1686 as monotherapy for the treatment of second-line EGFR mutant NSCLC in patients with the T790M mutation. The Breakthrough Therapy designation was granted based on interim efficacy and safety results from an ongoing Phase 1/2 study of CO-1686. CO-1686 is the Company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor, or EGFR, for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
18:26 EDTCLVSOn The Fly: After Hours Movers
Subscribe for More Information
16:25 EDTCLVSClovis to offer $200M of convertible senior notes due 2021 in private placement

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use